Trending NewsTrending NewsNYSE:NVO Novo Nordisk A/S (NVO) Stock Price, News & Analysis $51.06 +2.30 (+4.72%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$51.02 -0.04 (-0.08%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novo Nordisk A/S Stock (NYSE:NVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novo Nordisk A/S alerts:Sign Up Key Stats Today's Range$50.11▼$51.3050-Day Range$45.31▼$81.0752-Week Range$45.05▼$139.74Volume23.31 million shsAverage Volume24.77 million shsMarket Capitalization$227.98 billionP/E Ratio14.03Dividend Yield3.21%Price Target$93.67Consensus RatingHold Company Overview Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Read More Novo Nordisk A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreNVO MarketRank™: Novo Nordisk A/S scored higher than 84% of companies evaluated by MarketBeat, and ranked 150th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 9 hold ratings, and 2 sell ratings.Amount of Analyst CoverageNovo Nordisk A/S has only been the subject of 4 research reports in the past 90 days.Read more about Novo Nordisk A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth21.35% Earnings GrowthEarnings for Novo Nordisk A/S are expected to grow by 21.35% in the coming year, from $3.84 to $4.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 14.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.85.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 14.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.10.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 1.75. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 10.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.53% of the outstanding shares of Novo Nordisk A/S have been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novo Nordisk A/S has recently decreased by 8.25%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovo Nordisk A/S pays a meaningful dividend of 3.21%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovo Nordisk A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 45.05%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 35.19% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.Read more about Novo Nordisk A/S's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.53% of the outstanding shares of Novo Nordisk A/S have been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novo Nordisk A/S has recently decreased by 8.25%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.52 News SentimentNovo Nordisk A/S has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 134 news articles for Novo Nordisk A/S this week, compared to 49 articles on an average week.Search Interest204 people have searched for NVO on MarketBeat in the last 30 days. This is an increase of 149% compared to the previous 30 days.MarketBeat Follows67 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 109% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by InstitutionsOnly 11.54% of the stock of Novo Nordisk A/S is held by institutions.Read more about Novo Nordisk A/S's insider trading history. Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address NVO Stock News HeadlinesTrump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly (NVO)Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.August 9 at 10:00 AM | marketbeat.comMarketBeat Week in Review – 08/04 - 08/08 (NVO)Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales...August 9 at 7:00 AM | marketbeat.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year. | Weiss Ratings (Ad)Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? (NVO)Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.August 8 at 12:00 PM | marketbeat.comNovo Nordisk Stock Sinks—But Is a Bottom Finally In?Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings...August 5, 2025 | marketbeat.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel ...August 10 at 12:24 PM | gurufocus.com‘Time to Double Down,’ Says Top Investor About Novo Nordisk StockAugust 10 at 12:24 PM | msn.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVOAugust 10 at 12:00 PM | globenewswire.comSee More Headlines NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed this year? Novo Nordisk A/S's stock was trading at $86.02 on January 1st, 2025. Since then, NVO shares have decreased by 40.6% and is now trading at $51.06. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Wednesday, August, 6th. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The company earned $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 78.64% and a net margin of 35.60%. Read the conference call transcript. When did Novo Nordisk A/S's stock split? Shares of Novo Nordisk A/S split before market open on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly minted shares were payable to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Novo Nordisk A/S have any subsidiaries? The following companies are subsidiaries of Novo Nordisk A/S: Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and more. Who are Novo Nordisk A/S's major shareholders? Novo Nordisk A/S's top institutional investors include Jennison Associates LLC (0.42%), Kingstone Capital Partners Texas LLC (0.22%), Everett Harris & Co. CA (0.14%) and Sustainable Growth Advisers LP (0.14%). View institutional ownership trends. How do I buy shares of Novo Nordisk A/S? Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), ServiceNow (NOW), Advanced Micro Devices (AMD), Salesforce (CRM) and Eli Lilly and Company (LLY). Company Calendar Last Earnings8/06/2025Today8/10/2025Record date for 8/26 Dividend8/18/2025Ex-Dividend for 8/26 Dividend8/18/2025Dividend Payable8/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Large Cap Pharma Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVO CIK353278 Webwww.novonordisk.com Phone(454) 444-8888Fax45-4449-0555Employees77,349Year Founded1923Price Target and Rating Average Price Target for Novo Nordisk A/S$93.67 High Price Target$160.00 Low Price Target$57.00 Potential Upside/Downside+83.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$3.64 Trailing P/E Ratio14.03 Forward P/E Ratio13.30 P/E Growth1.54Net Income$14.64 billion Net Margins35.60% Pretax Margin45.11% Return on Equity78.64% Return on Assets24.51% Debt Debt-to-Equity Ratio0.52 Current Ratio0.78 Quick Ratio0.56 Sales & Book Value Annual Sales$311.94 billion Price / Sales0.73 Cash Flow$3.90 per share Price / Cash Flow13.09 Book Value$5.73 per share Price / Book8.91Miscellaneous Outstanding Shares4,465,000,000Free Float4,461,875,000Market Cap$227.98 billion OptionableOptionable Beta0.63 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NYSE:NVO) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.